How EMPAVELI can help | FATIGUE
Changes in fatigue
Changes in fatigue with EMPAVELI vs eculizumab—in people who had previously received a C5i (PEGASUS) Although it was not formally tested, people in the study were asked to report their changes in levels of fatigue at Week 16. Measuring fatigue improvement Fatigue was measured using the FACIT-Fatigue scale, a 13-question survey. In the survey, participants rated the level of impact they felt that their fatigue had on daily activities and function.
This information is for observation only and no conclusions can be made on the effect of EMPAVELI on fatigue. No comparisons can be made between those taking EMPAVELI and those taking eculizumab.
Average FACIT-Fatigue scores from beginning of study through Week 16
4-week run-in period (EMPAVELI + eculizumab)
16 weeks of EMPAVELI or eculizumab
20 25 30 35 40 45 50
This information is for observation only and no conclusions can be made on the effect of EMPAVELI on fatigue. No comparisons can be made between those taking EMPAVELI and those taking eculizumab.
43. 9
43.4
42. 2
42.5
43.6 average score for general US population
41. 8
41.0
40. 3
42. 8
32. 2
People taking EMPAVELI showed an improvement of
People taking C5i (eculizumab) showed a decrease of
32.7
32. 3
31.6
30. 8
30.7
30. 8
28.1
points
points
compared to their fatigue levels at the beginning of the study
compared to their fatigue levels at the beginning of the study
Week 2
Week 8
Baseline Day 1
Week 4 Week 6
Week 12
Week 16
EMPAVELI n eculizumab n 38 41
37 41
38 40
37 39
39 39
38 38
39 38
38 36
EMPAVELI
eculizumab
An increase of 5 or more points is seen as a clinically meaningful improvement.
The FACIT-Fatigue scale ranges from 0 to 52. Higher scores mean less fatigue. These data include people who did and did not get a transfusion during the study.
IMPORTANT SAFETY INFORMATION (cont’d) What are the possible side effects of EMPAVELI?
Andrea is an adult with PNH who's taken EMPAVELI.
EMPAVELI can cause serious side effects including allergic reactions. Allergic reactions can happen during your EMPAVELI infusion. Stop your EMPAVELI infusion and tell your healthcare provider or get emergency medical care right away if you get any of these symptoms during your EMPAVELI infusion: chest pain
Please see full Important Safety Information, including Boxed WARNING regarding risk of serious infections, on pages 38-39, and the full Prescribing Information and Medication Guide. C5i=C5 inhibitor; FACIT=Functional Assessment of Chronic Illness Therapy; PNH=paroxysmal nocturnal hemoglobinuria; SE=standard error.
trouble breathing or shortness of breath swelling of your face, tongue, or throat feel faint or pass out
18
19
Made with FlippingBook - professional solution for displaying marketing and sales documents online